Cerebrovascular Biomarkers in Alzheimer's Disease - LIDSEN Publishing Inc.丨The Open Access Publisher

(ISSN 2638-1311)

OBM Geriatrics is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21^st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes a variety of article types (Original Research, Review, Communication, Opinion, Comment, Conference Report, Technical Note, Book Review, etc.). There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Indexing:

COPE Crossref Google Scholar Dimensions J-Gate OpenAlex OUCI Scilit

Publication Speed (median values for papers published in 2024): Submission to First Decision: 6.3 weeks; Submission to Acceptance: 11.4 weeks; Acceptance to Publication: 7 days (1-2 days of FREE language polishing included)

Current Issue: 2025 Archive: 2024 2023 2022 2021 2020 2019 2018 2017

Special Issue

Cerebrovascular Biomarkers in Alzheimer's Disease

Submission Deadline: April 15, 2021 (Closed)

Guest Editor

Jacques De Reuck, MD, PhD

Professor, Université Lille 2, INSERM U1171 Degenerative & Vascular Cognitive Disorders, Lille, France

E-Mail

Research Interests: Dementia; cognitive impairment; Alzheimer's disease; ischemic stroke; neurodegenerative diseases; cerebrovascular diseases; vascular dementia

About This Topic

The significance of small cerebrovascular lesions is frequently overlooked in patients with Alzheimer’s disease. These lesions are most commonly due to cerebral amyloid angiopathy, which is mainly associated in the end-stages of the disease. Also Alzheimer’s disease can be mixed with arteriosclerotic small-vessel disease. The most common small cerebrovascular lesions are cortical micro-bleeds, cortical micro-infarcts, white matter changes, lacunar infarcts and superficial cortical siderosis. These lesions can be best detected with 7.0-tesla magnetic resonance imaging in vivo and on post-mortem examination, when the diagnosis of Alzheimer’s disease has to be confirmed for the family.
The final message is that in patients with suspected Alzheimer’s disease the vascular risk factors, such as arterial hypertension, hypercholesterolemia and diabetes, have to be treated as early as possible and smoking has to be avoided.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (geriatrics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Research Article

Comparison of Post-mortem 7.0-Tesla Magnetic Resonance Imaging of the Brains of Alzheimer Patients with and without Cerebral Amyloid Angiopathy

Jacques De Reuck ,

Florent Auger ,

Nicolas Durieux ,

Claude-Alain Maurage ,

Vincent Deramecourt ,

Charlotte Cordonnier ,

Florence Pasquier ,

Didier Leys and

Regis Bordet

Received: 24 September 2020; Published: 10 December 2020; doi: 10.21926/obm.geriatr.2004142

Abstract

Purpose: The influence of cerebral amyloid angiopathy (CAA) in Alzheimer’s disease (AD) remains unexplored. The present post-mortem study investigated possible differences in the degree of hippocampal atrophy (HA) between AD patients with and without CAA using 7.0-tesla magnetic resonance imaging (MRI). Also, the incidence of the hippocampal [...]

Newsletter

TOP